[4]Müller TD,Finan B,Bloom SR,et al.Glucagon-like peptide 1(GLP-1).Mol Metab 2019;30:72-130. [5]Pelle MC,et al.Role of a Dual Glucose-Dependent Insulinotropic Peptide(GIP)/Glucagon-like Peptide-1 Receptor Agonist(Twincretin)in Glycemic Control:From Pathophysiology to Treatment.Life(Basel...
除了胰高血糖素样肽1(GLP-1)受体激动剂在不断发展外,近年来,将葡萄糖依赖性促胰岛素多肽(GIP)和GLP-1相结合治疗糖尿病也取得重大突破。 Tirzepatide是一种GIP和GLP-1受体双重激动剂。近期,这款药物治疗2型糖尿病的重要3期临床试验结果(SURPASS-2),在美国糖尿病学会(ADA)2021年会公布,并同步发表在著名期刊《...
a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180-2193. doi:10.1016/S0140-6736(18)32260-8
近期,柳叶刀杂志上发表礼来公司“LY3437943,一种新型药物,葡萄糖依赖性促胰岛素多肽(GIP)/胰高糖素样肽-1(GLP-1)/胰高血糖素(GCG)受体三重激动剂在2型糖尿病患者的多中心、随机双盲、安慰剂对照、多剂量递增I期临床试验”的研究结果,或许将为肥胖症的治疗带来契机。 研究共筛选了210名2型糖尿病患者,纳入标准...
如果经过更长考察时间的临床试验,其有效性、安全性和耐受性得到确认,那么,GLP-1/GIP/GCG三重受体激动剂可能成为糖尿病、高血压及心血管疾病的预防和治疗药物。 参考文献 (上下滑动可查看) [1] Shweta Urva, et al. LY3437943, a...
[6]Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1 Trends Endocrinol Metab 2020;31:410-421. [7]Coskun T,Sloop KW,Loghin C,et al.LY3298176,a novel dual GIP and GLP-1 receptor agonist fo...
[6]Samms RJ,Coghlan MP,Sloop KW.How may GIP enhance the therapeutic efficacy of GLP-1 Trends Endocrinol Metab 2020;31:410-421. [7]Coskun T,Sloop KW,Loghin C,et al.LY3298176,a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus:from discovery to cl...
the first and only GIP and GLP-1 receptor agonist for the treatment of adults withtype 2 diabetes. Retrieved May 13, 2022, fromhttps://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-receptor-agonist-for-the-treatment-of...
另外, Mounjaro尚未在有胰腺炎病史的患者中进行过研究,并且不适用于 1 型糖尿病患者。 参考来源:FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.新闻发布,Eli Lilly and Company;2022年5月...
另外, Mounjaro尚未在有胰腺炎病史的患者中进行过研究,并且不适用于 1 型糖尿病患者。 参考来源:FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.新闻发布,Eli Lilly and Company;2022年5月...